
Cytos to raise up to CHF37 million from international and strategic investors to advance asthma clinical program
Cytos Biotechnology Ltd, a Swiss biotech company developing a new class of biopharmaceutical products called Immunodrugs, has signed agreements with an international syndicate of strategic investors to raise a total of up to CHF37 million (USD40 million) in equity and debt. The investment round is being led by venBio and
